Skip to content

A randomized controlled trial: the duration of anticoagulant therapy in pregnancy for recurrent abortion with antiphospholipid syndrome

A randomized controlled trial: the duration of anticoagulant therapy in pregnancy for recurrent abortion with antiphospholipid syndrome

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083052
Enrollment
Unknown
Registered
2024-04-15
Start date
2024-05-01
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent spontaneous abortion and obstetric antiphospholipid antibody syndrome

Interventions

study group:The duration of anticoagulant therapy is determined by the patients antibody titer. Start to use LDA 75mg, oral once a day, before pregnancy LDA duration is not limited. Add LMWH 4000IU on
Antibody titers were measured once in the first trimester, and the titers of aPL tested positive before pregnancy were measured monthly starting from 12 weeks. Antibody turned negative for two consecu
Regular Group:Start to use LDA 75mg, oral once a day, before pregnancy LDA duration is not limited. LMWH 4000IU was added once daily subcutaneous injection from confirmation of pregnancy to LDA+LMWH a

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1: Patients with recurrent miscarriage and antiphospholipid antibody syndrome 2: aged between 20 years old and 40 years old 3: Good compliance, sign informed consent form before the experiment

Exclusion criteria

Exclusion criteria: 1: recurrent miscarriage caused by reasons other than the presence of antiphospholipid antibodies 2: good compliance, sign informed consent form before the experiment 3: a history of thrombosis and a history of fetal arrest in the middle and late stages of pregnancy 4: History of premature birth due to severe eclampsia or preeclampsia or severe placental dysfunction 5: Have a history of allergies to low molecular weight heparin or aspirin enteric coated tablets 6: Previous history of gastrointestinal ulcers or gastric bleeding disease 7: Individuals with a history of malignant tumors 8: Patients with mental illness 9: Epilepsy and other neurological disorders

Design outcomes

Primary

MeasureTime frame
live birth rate;

Secondary

MeasureTime frame
abortion;Delayed intrauterine development of the fetus;premature delivery;Hypertensive disorder complicating pregnancy;birth defect ;postpartum hemorrhage;Dose and cost of using LMWH during pregnancy;

Countries

China

Contacts

Public ContactHaiyan Wang

Peking University Third Hospital

wangquan1991@sina.com+86 136 6131 9838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026